Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anteris Technologies Global Corp.AVR · Entity 5089 | Director | June 07, 2026 | June 10, 2026 |
| Evommune, Inc.EVMN · Entity 5539 | Chief Business & Legal Officer | May 28, 2026 | June 02, 2026 |
| MeiraGTx Holdings plcMGTX · Entity 4734 | Director | June 08, 2018 | June 08, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anteris Technologies Global Corp.
Report date June 07, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,580 |
Reported balance
After 2026-06-07 transaction · row 1
1 source rowRow 1 · 2026-06-07 · Exercise / conversion · Acquired 17,580 · Balance 17,580 F1: Each restricted stock unit ("RSU") converts into a share of common stock on a one-for-one basis. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 35,162 |
Reported balance
After 2026-06-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-07 · Exercise / conversion · Disposed 17,580 · Balance 35,162 F1: Each restricted stock unit ("RSU") converts into a share of common stock on a one-for-one basis. F2: On December 3, 2025, the reporting person was granted 52,742 RSUs that generally vest in approximately equal installments on June 7, 2026, June 7, 2027 and June 7, 2028, subject to the Reporting Person's continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") converts into a share of common stock on a one-for-one basis.
F2: On December 3, 2025, the reporting person was granted 52,742 RSUs that generally vest in approximately equal installments on June 7, 2026, June 7, 2027 and June 7, 2028, subject to the Reporting Person's continued service through each vesting date.
Evommune, Inc.
Report date May 28, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,835 |
Ending reported balance
After 2026-05-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-28 · Exercise / conversion · Acquired 14,223 · Balance 75,058 F1: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2026. Row 2 · 2026-05-28 · Sale · Disposed 14,223 · Balance 60,835 F1: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2026. F2: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2034-03-21 | Direct | 47,845 |
Reported balance
After 2026-05-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-28 · Exercise / conversion · Disposed 14,223 · Balance 47,845 F1: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2026. F4: One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 3,175 |
Reported balance
Holding disclosure · report date 2026-05-28 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,175 F3: The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2026.
F2: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F3: The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
F4: One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
MeiraGTx Holdings plc
Report date June 08, 2018 · Filed June 08, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 41,285 |
Reported balance
Holding disclosure · report date 2018-06-08 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 41,285 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kadmon Holdings, Inc.
Report date November 09, 2021 · Filed November 09, 2021
Section 16 reporting ended · disclosed 2021-11-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 1
1 source rowRow 1 · 2021-11-09 · Disposition to issuer · Disposed 17,671 · Balance 0 F1: Disposed pursuant to the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger (the "Merger"). |
| Stock Appreciation RightSEC Table II · derivative / convertible security · Conversion / exercise price $4.66 · Expires 2026-12-15 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-09 · Disposition to issuer · Disposed 75,000 · Balance 0 F3: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR. F2: In connection with the Merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award. |
| Performance Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.64 · Expires 2027-12-08 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-09 · Disposition to issuer · Disposed 150,000 · Balance 0 F3: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR. F2: In connection with the Merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.47 · Expires 2028-12-14 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-09 · Disposition to issuer · Disposed 75,000 · Balance 0 F3: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR. F2: In connection with the Merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2029-08-30 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-11-09 · Disposition to issuer · Disposed 300,000 · Balance 0 F3: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR. F2: In connection with the Merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.34 · Expires 2030-01-27 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-11-09 · Disposition to issuer · Disposed 360,000 · Balance 0 F3: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR. F2: In connection with the Merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.96 · Expires 2031-01-08 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-11-09 · Disposition to issuer · Disposed 680,000 · Balance 0 F3: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR. F2: In connection with the Merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award. |
| Equity Appreciation Rights UnitSEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2024-12-31 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-11-09 · Disposition to issuer · Disposed 200 · Balance 0 F3: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR. F2: In connection with the Merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed pursuant to the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger (the "Merger").
F2: In connection with the Merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award.
F3: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 07, 2026 Filed Jun 10, 2026 01:46 UTC | Anteris Technologies Global Corp. AVR · Entity 5089 | Exercise / conversionRestricted Stock Units · Derivative | 17,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-024701 · form4.xml · derivative · entry 2 Moss Gregory S. · CIK 0001742496 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,162 Underlying: Common Stock · 17,580 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") converts into a share of common stock on a one-for-one basis. F2 · derivative.exercise_date: On December 3, 2025, the reporting person was granted 52,742 RSUs that generally vest in approximately equal installments on June 7, 2026, June 7, 2027 and June 7, 2028, subject to the Reporting Person's continued service through each vesting date. F2 · derivative.expiration_date: On December 3, 2025, the reporting person was granted 52,742 RSUs that generally vest in approximately equal installments on June 7, 2026, June 7, 2027 and June 7, 2028, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| June 07, 2026 Filed Jun 10, 2026 01:46 UTC | Anteris Technologies Global Corp. AVR · Entity 5089 | Exercise / conversionCommon Stock | 17,580 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-024701 · form4.xml · nonDerivative · entry 1 Moss Gregory S. · CIK 0001742496 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") converts into a share of common stock on a one-for-one basis. Read SEC document |
| May 28, 2026 Filed Jun 2, 2026 00:00 UTC | Evommune, Inc. EVMN · Entity 5539 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 14,223 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001742496-26-000005 · primarydocument.xml · derivative · entry 4 Moss Gregory S. · CIK 0001742496 · Chief Business & Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,845 Underlying: Common Stock · 14,223 shares Expires 2034-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2026. F4 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| May 28, 2026 Filed Jun 2, 2026 00:00 UTC | Evommune, Inc. EVMN · Entity 5539 | SaleCommon Stock | 14,223 | $22.83 | $324,711.09 |
DisclosureSEC source: 0001742496-26-000005 · primarydocument.xml · nonDerivative · entry 2 Moss Gregory S. · CIK 0001742496 · Chief Business & Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,835 F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 28, 2026 Filed Jun 2, 2026 00:00 UTC | Evommune, Inc. EVMN · Entity 5539 | Exercise / conversionCommon Stock | 14,223 | $1.71 | $24,321.33 |
DisclosureSEC source: 0001742496-26-000005 · primarydocument.xml · nonDerivative · entry 1 Moss Gregory S. · CIK 0001742496 · Chief Business & Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,058 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2026. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 21:23 UTC | Evommune, Inc. EVMN · Entity 5539 | GrantEmployee Stock Option (Right to Buy) · Derivative | 115,279 | $0.00 Strike: $26.77 | $0.00 |
DisclosureSEC source: 0001742496-26-000003 · primarydocument.xml · derivative · entry 1 Moss Gregory S. · CIK 0001742496 · Chief Business & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,279 Underlying: Common Stock · 115,279 shares Expires 2036-04-15 F1 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:22 UTC | Evommune, Inc. EVMN · Entity 5539 | Tax withholdingCommon Stock | 13,624 | $17.84 | $243,052.16 |
DisclosureSEC source: 0001742496-25-000012 · primarydocument.xml · nonDerivative · entry 1 Moss Gregory S. · CIK 0001742496 · Chief Business & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,835 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 23:30 UTC | Anteris Technologies Global Corp. AVR · Entity 5089 | GrantRestricted Stock Units · Derivative | 13,821 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-044608 · form4.xml · derivative · entry 2 Moss Gregory S. · CIK 0001742496 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,821 Underlying: Common Stock · 13,821 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a right to receive one share of common stock. These RSU vest on the earlier of the first anniversary of the grant date and the date of the next occurring annual stockholders meeting, subject to continued service through the vesting date. F2 · derivative.exercise_date: Each RSU represents a right to receive one share of common stock. These RSU vest on the earlier of the first anniversary of the grant date and the date of the next occurring annual stockholders meeting, subject to continued service through the vesting date. F2 · derivative.expiration_date: Each RSU represents a right to receive one share of common stock. These RSU vest on the earlier of the first anniversary of the grant date and the date of the next occurring annual stockholders meeting, subject to continued service through the vesting date. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 23:30 UTC | Anteris Technologies Global Corp. AVR · Entity 5089 | GrantRestricted Stock Units · Derivative | 52,742 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-044608 · form4.xml · derivative · entry 1 Moss Gregory S. · CIK 0001742496 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,742 Underlying: Common Stock · 52,742 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a right to receive one share of common stock. These RSU vest in three approximately equal annual installments on June 7, 2026, 2027 and 2028, subject to the Reporting Person's continued service through each vesting date. F1 · derivative.exercise_date: Each RSU represents a right to receive one share of common stock. These RSU vest in three approximately equal annual installments on June 7, 2026, 2027 and 2028, subject to the Reporting Person's continued service through each vesting date. F1 · derivative.expiration_date: Each RSU represents a right to receive one share of common stock. These RSU vest in three approximately equal annual installments on June 7, 2026, 2027 and 2028, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:20 UTC | Evommune, Inc. EVMN · Entity 5539 | ConversionSeries B Preferred Stock · Derivative | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001742496-25-000010 · form4-11122025_091142.xml · derivative · entry 3 Moss Gregory S. · CIK 0001742496 · Chief Business & Legal Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 3,175 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date. F1 · price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date. F2 · ownership.nature: The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:20 UTC | Evommune, Inc. EVMN · Entity 5539 | ConversionCommon Stock | 3,175 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001742496-25-000010 · form4-11122025_091142.xml · nonDerivative · entry 1 Moss Gregory S. · CIK 0001742496 · Chief Business & Legal Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 3,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date. F2 · ownership.nature: The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:15 UTC | Evommune, Inc. EVMN · Entity 5539 | GrantEmployee Stock Option (Right to Buy) · Derivative | 293,496 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001742496-25-000008 · form4-11072025_041104.xml · derivative · entry 1 Moss Gregory S. · CIK 0001742496 · Chief Business & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293,496 Underlying: Common Stock · 293,496 shares Expires 2035-11-04 F1 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on November 5, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 22:39 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerEquity Appreciation Rights Unit · Derivative | 200 | $3.50 Strike: $6.00 | $700.00 |
DisclosureSEC source: 0001104659-21-136407 · tm2131118-7_4seq1.xml · derivative · entry 8 Moss Gregory S. · CIK 0001742496 · EVP, Gen. Coun. / CCO. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 200 shares Expires 2024-12-31 F3 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR. F2 · derivative.exercise_date: In connection with the Merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 22:39 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 680,000 | $5.54 Strike: $3.96 | $3,767,200.00 |
DisclosureSEC source: 0001104659-21-136407 · tm2131118-7_4seq1.xml · derivative · entry 7 Moss Gregory S. · CIK 0001742496 · EVP, Gen. Coun. / CCO. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 680,000 shares Expires 2031-01-08 F3 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR. F2 · derivative.exercise_date: In connection with the Merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 22:39 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 360,000 | $5.16 Strike: $4.34 | $1,857,600.00 |
DisclosureSEC source: 0001104659-21-136407 · tm2131118-7_4seq1.xml · derivative · entry 6 Moss Gregory S. · CIK 0001742496 · EVP, Gen. Coun. / CCO. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 360,000 shares Expires 2030-01-27 F3 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR. F2 · derivative.exercise_date: In connection with the Merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 22:39 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 300,000 | $7.36 Strike: $2.14 | $2,208,000.00 |
DisclosureSEC source: 0001104659-21-136407 · tm2131118-7_4seq1.xml · derivative · entry 5 Moss Gregory S. · CIK 0001742496 · EVP, Gen. Coun. / CCO. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 300,000 shares Expires 2029-08-30 F3 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR. F2 · derivative.exercise_date: In connection with the Merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 22:39 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 75,000 | $7.03 Strike: $2.47 | $527,250.00 |
DisclosureSEC source: 0001104659-21-136407 · tm2131118-7_4seq1.xml · derivative · entry 4 Moss Gregory S. · CIK 0001742496 · EVP, Gen. Coun. / CCO. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 75,000 shares Expires 2028-12-14 F3 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR. F2 · derivative.exercise_date: In connection with the Merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 22:39 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerPerformance Stock Option (right to buy) · Derivative | 150,000 | $5.86 Strike: $3.64 | $879,000.00 |
DisclosureSEC source: 0001104659-21-136407 · tm2131118-7_4seq1.xml · derivative · entry 3 Moss Gregory S. · CIK 0001742496 · EVP, Gen. Coun. / CCO. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 150,000 shares Expires 2027-12-08 F3 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR. F2 · derivative.exercise_date: In connection with the Merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 22:39 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Appreciation Right · Derivative | 75,000 | $4.84 Strike: $4.66 | $363,000.00 |
DisclosureSEC source: 0001104659-21-136407 · tm2131118-7_4seq1.xml · derivative · entry 2 Moss Gregory S. · CIK 0001742496 · EVP, Gen. Coun. / CCO. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 75,000 shares Expires 2026-12-15 F3 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR. F2 · derivative.exercise_date: In connection with the Merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 22:39 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerCommon Stock | 17,671 | $9.50 | $167,874.50 |
DisclosureSEC source: 0001104659-21-136407 · tm2131118-7_4seq1.xml · nonDerivative · entry 1 Moss Gregory S. · CIK 0001742496 · EVP, Gen. Coun. / CCO. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed pursuant to the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger (the "Merger"). Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:28 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantStock Option (right to buy) · Derivative | 680,000 | $0.00 Strike: $3.96 | $0.00 |
DisclosureSEC source: 0001593968-21-000121 · primary_01.xml · derivative · entry 1 Moss Gregory S. · CIK 0001742496 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 680,000 Underlying: Common stock, par value $0.001 · 680,000 shares Expires 2031-01-08 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal annual installments over 3 years from January 8, 2021, the date of grant. Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 21:29 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantStock Option (right to buy) · Derivative | 360,000 | $0.00 Strike: $4.34 | $0.00 |
DisclosureSEC source: 0001593968-20-000233 · primary_01.xml · derivative · entry 1 Moss Gregory S. · CIK 0001742496 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,000 Underlying: Common stock, par value $0.001 · 360,000 shares Expires 2030-01-27 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal annual installments over 3 years from January 27, 2020, the date of grant. Read SEC document |
| August 30, 2019 Filed Aug 30, 2019 21:09 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantStock Option (right to buy) · Derivative | 300,000 | $2.14 Strike: $2.14 | $642,000.00 |
DisclosureSEC source: 0001593968-19-001827 · primary_01.xml · derivative · entry 1 Moss Gregory S. · CIK 0001742496 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common stock, par value $0.001 · 300,000 shares Expires 2029-08-30 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal annual installments over 3 years from August 30, 2019, the date of grant. F2 · balance_after: Only represents derivative securities of this class. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.